2026 New Year’s Greetings from the CEO MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) provides shareholders a corporate update in the following Letter to

#MNOV 2026 New Year’s Greetings from the CEO

www.stocktitan.net/news/MNOV/2026-new-year-...

MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy MediciNova (NASDAQ:MNOV) announced completion of patient enrollment in the randomized, placebo-controlled Phase 2 OXTOX study evaluating MN-166 (ibudilast) to prevent chemotherapy-induced peripheral neuropathy in metastatic colorectal cancer.A total of 100 patients were randomized across two arms at 11 clinical sites in Australia. Patient recruitment is closed; participants continue chemotherapy with assigned study drug until disease progression or unacceptable toxicity. The study will conclude when the final patient reaches six months post-chemotherapy. Top-line data are anticipated later in 2026, though no exact completion date is provided.

#MNOV MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

www.stocktitan.net/news/MNOV/medici-nova-an...

Message from the CEO to MediciNova Shareholders MediciNova (MNOV) reported a peer-reviewed publication showing MN-002, the primary metabolite of MN-001, increases cholesterol efflux by upregulating ABCA1 and ABCG1 in macrophages, a mechanism tied to Reverse Cholesterol Transport.The company completed patient enrollment in its Phase 2 MN-001-NATG-202 randomized, double-blind, placebo-controlled trial in hypertriglyceridemia and NAFLD due to T2DM; top-line results are expected by summer 2026. Management says the mechanistic data reinforce prior clinical lipid-profile observations and will inform next steps toward advancing MN-001 as a potential first-in-class therapy for metabolic and cardiovascular disease.

#MNOV Message from the CEO to MediciNova Shareholders

www.stocktitan.net/news/MNOV/message-from-t...

Trade Alerts, Tuesday November 4, 2025 – Crystal Equity Research

Small-cap stocks in new uptrend, average directional index, Tue Nov 4th - #MRT #APUS #TRST #MNOV #JRVR #IHRT #GLDD #CSTL #SMHI #AMTD - More: crystalequityresearch.com/trade-alerts... - #smallcap

MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) MediciNova (NASDAQ:MNOV) announced completion of patient enrollment in the Phase 2 MN-001-NATG-202 trial of MN-001 (tipelukast) for hypertriglyceridemia and NAFLD due to Type 2 diabetes.The multi-center, randomized, double-blind, placebo-controlled study randomizes patients 1:1 to 500 mg/day MN-001 or placebo for 24 weeks. Co-primary endpoints are change in liver fat by CAP score and change in fasting serum triglycerides at Week 24. Secondary endpoints include safety, tolerability, and changes in HDL-C, LDL-C, and total cholesterol. Patient recruitment is closed and top-line data are expected by summer 2026.

#MNOV MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

www.stocktitan.net/news/MNOV/medici-nova-an...

MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ

#MNOV MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication

www.stocktitan.net/news/MNOV/medici-nova-co...

234 ALS Patients Enrolled: MediciNova's Fast-Track Drug Trial Could Offer New Hope for Fatal Disease MediciNova completes enrollment of 234 patients in COMBAT-ALS trial studying MN-166 for ALS treatment. Double-blind study across US and Canada. Top-line results expected end-2026.

#MNOV MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)

www.stocktitan.net/news/MNOV/medici-nova-an...

Key ALS Clinical Trial Results: MediciNova's COMBAT-ALS Study Featured at Major Symposium MediciNova's Phase 2b/3 COMBAT-ALS trial of MN-166 (ibudilast) selected for poster presentation at 36th International ALS/MND Symposium in San Diego, December 5-7, 2025.

#MNOV MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND

www.stocktitan.net/news/MNOV/medici-nova-an...

Major ALS Treatment Milestone: MediciNova Completes COMBAT-ALS Trial Enrollment with $22M NIH Grant Support Biotech firm MediciNova achieves target enrollment in COMBAT-ALS Phase 2b/3 trial of MN-166, secures $30M equity purchase agreement, and advances NIH-funded $22M expanded access program.

#MNOV MediciNova Provides Shareholder Update on Key Developments

www.stocktitan.net/news/MNOV/medici-nova-pr...

Major ALS Treatment Breakthrough: MediciNova Reaches Full Enrollment in Pivotal COMBAT-ALS Study Biotech firm MediciNova announces completion of patient enrollment in Phase 2b/3 COMBAT-ALS trial of MN-166 (ibudilast) across US and Canada sites, advancing ALS treatment research.

#MNOV MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial

www.stocktitan.net/news/MNOV/medici-nova-ac...

MediciNova Lands Strategic $30M Equity Deal: What This Means for Its Biotech Pipeline New $30M equity purchase agreement provides MediciNova flexible funding for R&D advancement without warrants. See how this strategic deal impacts growth potential. Learn more.

#MNOV MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million

www.stocktitan.net/news/MNOV/medici-nova-an...

MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials MediciNova (NASDAQ:MNOV) reported significant progress in two key clinical trials. The Phase 2/3 COMBAT-ALS trial for MN-166 (ibudilast) is now down to single-digit patient enrollment requirements. Additionally, their Phase 2 trial studying MN-001 (tipelukast) for dyslipidemia and fatty liver disease in type 2 diabetes patients needs only two more participants.The company's ALS program includes a large Expanded Access Program (EAP) supported by a $22 million NIH grant. MediciNova expects to engage in FDA regulatory discussions and anticipates top-line data by the end of 2026.

#MNOV MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials

www.stocktitan.net/news/MNOV/medici-nova-pr...

Major Breakthrough: NIH Funds New ALS Treatment Trial for 200 Advanced-Stage Patients NIH funds expanded access trial of MN-166 for 200 advanced ALS patients, offering hope beyond current Phase 2/3 study. See full trial implications.

#MNOV First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

www.stocktitan.net/news/MNOV/first-patient-...

#MNOV MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

www.stocktitan.net/news/MNOV/medici-nova-ce...

#MNOV MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

www.stocktitan.net/news/MNOV/medici-nova-re...

BREAKING NEWS: ( NASDAQ: #MNOV ) MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

#StockMarket #News